William Blair began coverage on shares of Korro Bio (NASDAQ:KRRO – Free Report) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The firm issued an outperform rating and a $180.00 price objective on the stock.
Other equities research analysts have also recently issued reports about the company. BMO Capital Markets reaffirmed an outperform rating and set a $120.00 price target on shares of Korro Bio in a report on Wednesday, May 15th. HC Wainwright reaffirmed a buy rating and set a $100.00 price target on shares of Korro Bio in a report on Tuesday, May 21st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average target price of $135.00.
View Our Latest Stock Report on KRRO
Korro Bio Price Performance
Korro Bio (NASDAQ:KRRO – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.04). On average, sell-side analysts forecast that Korro Bio will post -9.64 EPS for the current fiscal year.
Institutional Investors Weigh In On Korro Bio
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Atlas Venture Life Science Advisors LLC increased its holdings in Korro Bio by 1.6% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock valued at $38,515,000 after purchasing an additional 17,857 shares during the last quarter. NEA Management Company LLC grew its stake in Korro Bio by 1.7% in the second quarter. NEA Management Company LLC now owns 1,090,793 shares of the company’s stock valued at $36,945,000 after acquiring an additional 17,857 shares during the period. Eventide Asset Management LLC acquired a new position in Korro Bio in the fourth quarter valued at about $26,185,000. 72 Investment Holdings LLC acquired a new position in Korro Bio in the fourth quarter valued at about $13,269,000. Finally, Monashee Investment Management LLC acquired a new position in Korro Bio in the fourth quarter valued at about $4,352,000. Institutional investors own 13.18% of the company’s stock.
Korro Bio Company Profile
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Further Reading
- Five stocks we like better than Korro Bio
- How to Choose Top Rated Stocks
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Walmart Stock: Buy the Rip or Wait for the Dip?
- How Can Investors Benefit From After-Hours Trading
- 3 Stocks to Buy for a Soft Landing, If There Is One
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.